Why Abzena?
Trust our focused approach.
At BioProcess International Europe in Vienna, our Sr. Manager of Cell Line Development, Dr Tanya Knight, presented a poster titled “AbZelectPRO: Achieving high-titer productivity & accelerated timelines with enhanced cell line platforms.” The newly enhanced and fully integrated cell line development platform offers additions, including two GS Knockout cell lines (Revvity CHOSOURCE), increased productivity, proven performance, and rapid timelines, enabling biopharma customers to progress from DNA to GMP with flexibility and ease.
Abstract
Our fully integrated AbZelectPRO platform enables the rapid delivery of stable, high-producing cell lines to support the production of complex biologics. The platform combines our AbZelectPRO CHO-K1 and AbZelectPRO -KO GS knockout cell lines together with ProteoNic’s 2G UNic® premium vector technology and an optimized process to generate fast-doubling, higher-producing, scalable cell lines expressing up to 10 g/L of product. This accelerated platform enables you to achieve stable pools in 3 weeks and go from DNA to RCB in just 10 weeks & GMP in 6 months.
The AbZelectPRO platform supports a diverse range of modalities from antibodies and more difficult-to-express proteins such as fusion proteins, bispecifics, vaccines and other novel modalities. Furthermore, the platform enables program de-risking by using early material generation from stable pools to remove activities such as downstream method development and formulation development from the critical path. Backed by our comprehensive analytics portfolio, the AbZelectPRO platform simplifies the development process and helps to deliver therapeutic proteins successfully to the clinic.
Poster authors include: Brett Verstak*, Blanca San Miguel, Oscar Swindley , Nathan Courtier, Kean Huedepohl, Ned Swift, Miles Wellington, Sophie Douglas, Noah Collins, Elizabeth Willows, Tania Fisher, Kalpana Wood, Tanya Knight, Beata Blaszczyk, Nicole Wakes, Rob Holgate
Abzena has over two decades of expertise in developing over 200+ cell lines. Click here for more information about our robust and flexible cell line development services.